Emerging management and its impact on radioiodine refractory differentiated thyroid cancer
10.19538/j.cjps.issn1005-2208.2019.03.07
- Author:
Yan-qing LIU
1
;
Yan-song LIN
1
Author Information
1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing 100730,China
- Publication Type:Journal Article
- Keywords:
radioiodine refractory differentiated thyroid cancer;
targeted therapy;
immunotherapy;
peptide receptor radionuclide therapy
- From:
Chinese Journal of Practical Surgery
2019;39(03):216-220
- CountryChina
- Language:Chinese
-
Abstract:
Differentiated thyroid cancer(DTC) generally carries good prognosis through standard treatment. While,it could dedifferentiate into radioiodine refractory differentiated thyroid cancer(RAIR-DTC),which progresses rapidly with high mortality and limited treatment methods. Recently,along with the increasing of studies on genetic features,signal transduction pathways and immune microenvironment of RAIR-DTC,as well as the development of new radionuclide tracers,more theoretical bases have been provided for the targeted therapy of RAIR-DTC.
